A Phase 1/2 interventional study of RX-3117 in Solid Tumor and Metastatic Bladder Cancer, sponsored by Processa Pharmaceuticals. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-06.
Sponsored by Processa Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 883 studies in Urinary Bladder Neoplasms with a site in United States — 162 open to participants now, 269 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.
Among the 883 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 185th largest by enrollment of the 715 interventional ones that give a count, is one of 27 that started in 2013, is one of 83 in phase 1/2, and was the 297th registered.
1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →162 of the 883 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
SystImmune Inc. · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
883 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 281 · Phase 2 330 · Phase 3 88 · Phase 4 7
First in 1988; this study’s year is marked. 27 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is above the median of 60 across 1,299 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 46 across the 715 interventional studies, 180 across the 145 observational. Of the 562 that completed or were terminated, 253 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
314 of 883 have an industry lead sponsor. The 10 most frequent:
Processa Pharmaceuticals is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Processa Pharmaceuticals has 1 study filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
97 of the studies in Urinary Bladder Neoplasms with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06111235Phase 3CG Oncology, Inc.A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | 2026-11 |
| NCT04658862Phase 3Janssen Research & Development, LLCA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | 2026-12-30 |
| NCT06525571Phase 3Johns Hopkins UniversityOutcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection | 2027-01-04 |
| NCT05911295Phase 3Seagen, a wholly owned subsidiary of PfizerDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | 2027-01-29 |
| NCT04241185Phase 3Merck Sharp & Dohme LLCEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | 2027-01-31 |
Add all 97 to your calendar (.ics) → With an account.
Among the 883 studies in Urinary Bladder Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced bladder cancer).
This is a dose-finding, open-label, single agent study of RX-3117. Once the maximum tolerated dose is identified additional subjects will be treated in a dose expansion followed by a 2-stage Phase 2 study. Subjects will be treated for up to 8 cycles of therapy. A cycle will be 4 weeks. RX-3117 dosing will be 3 times each week for 3 weeks follow by 1 week off treatment. All subjects will be followed for at least 30 days after the last dose of RX-3117.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will receive RX-3117.
Drug: RX-3117
Overall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1
Number of subjects participating in Phase 1 that experienced a DLT during the first cycle of treatment (28 days)
Time frame: 28 days
Overall Safety Profile Characterized by Number of Subjects Experiencing Serious Adverse Events in Phase 1
Number of subjects participating in Phase 1 that experience any SAEs
Time frame: through study completion, up to 224 days (8 cycles of treatment)
Overall Safety Profile Characterized by the Number of Subjects That Discontinue Study Treatment - Phase 1
Number of subjects participating in Phase 1 of study that discontinued study treatment due to a treatment emergent adverse event.
Time frame: through study completion, up to 224 days (8 cycles of treatment)
Overall Safety Profile Characterized by Number of Subjects Experiencing a Treatment Emergent Adverse Event- Phase 1
Number of subjects that experience any treatment-related adverse event.
Time frame: through study completion, up to 224 days (8 cycles of treatment)
Progression Free Survival (Phase 2)
Progression Free Survival in Phase 2 of the study for pancreatic and bladder cancer subjects.
Time frame: 4 months
Area Under the Plasma Concentration Time Curve (AUC) (Phase 1)
Time frame: Pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours after oral administration in Cycle 1 Days 1 and 15
Best Overall Response Rate (Phase 2)
Best Overall Response Rate (includes Complete Response, Partial Response, and Stable Disease)
Time frame: Baseline and at 4, 8, 12, 16 and 32 weeks
Biomarker Concentrations in Blood (Phase 1 and Phase 2)
Analysis of biomarker data not conducted. Biomarker samples were not analyzed due to previous sponsor terminating clinical program.
Time frame: Baseline and 4, 8, 12, 16 and 32 weeks
| Milestone | RX-3117 30 mg, 3 Times/Week | RX-3117 60 mg, 3 Times/Week | RX-3117 100 mg, 3 Times/Week | RX-3117 150 mg, 3 Times/Week | RX-3117 200 mg, 3 Times/Week | RX-3117 500 mg, 3 Times/Week | RX-3117 1000 mg, 3 Times/Week | RX 3117 1500 mg, 3 Times/Week | RX-3117 2000 mg, 3 Times/Week | RX-3117 500 mg, 5 Times/Week | RX-3117 700 mg, 5 Times/Week | RX-3117 500 mg, 7 Times/Week | RX-3117 700 mg 5 Times/Week (Phase 2 Portion of Study) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 3 | 3 | 3 | 3 | 3 | 4 | 6 | 3 | 11 | 3 | 80 |
| Completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 6 | 3 | 11 | 3 | 80 |
| Withdrew: Disease progression | 1 | 1 | 2 | 2 | 3 | 2 | 3 | 3 | 4 | 3 | 7 | 2 | 59 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 6 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 4 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 8 |
Number of subjects participating in Phase 1 that experienced a DLT during the first cycle of treatment (28 days)
| Participants | RX-3117 30 mg, 3 Times/Week | RX-3117 60 mg, 3 Times/Week | RX-3117 100 mg, 3 Times/Week | RX-3117 150 mg, 3 Times/Week | RX-3117 200 mg, 3 Times/Week | RX-3117 500 mg, 3 Times/Week | RX-3117 1000 mg, 3 Times/Week | RX 3117 1500 mg, 3 Times/Week | RX-3117 2000 mg, 3 Times/Week | RX-3117 500 mg, 5 Times/Week | RX-3117 700 mg, 5 Times/Week | RX-3117 500 mg, 7 Times/Week |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
Number of subjects participating in Phase 1 that experience any SAEs
| Participants | RX-3117 30 mg, 3 Times/Week | RX-3117 60 mg, 3 Times/Week | RX-3117 100 mg, 3 Times/Week | RX-3117 150 mg, 3 Times/Week | RX-3117 200 mg, 3 Times/Week | RX-3117 500 mg, 3 Times/Week | RX-3117 1000 mg, 3 Times/Week | RX 3117 1500 mg, 3 Times/Week | RX-3117 2000 mg, 3 Times/Week | RX-3117 500 mg, 5 Times/Week | RX-3117 700 mg, 5 Times/Week | RX-3117 500 mg, 7 Times/Week |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Safety Profile Characterized by Number of Subjects Experiencing Serious Adverse Events in Phase 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 5 | 1 |
Number of subjects participating in Phase 1 of study that discontinued study treatment due to a treatment emergent adverse event.
| Participants | RX-3117 30 mg, 3 Times/Week | RX-3117 60 mg, 3 Times/Week | RX-3117 100 mg, 3 Times/Week | RX-3117 150 mg, 3 Times/Week | RX-3117 200 mg, 3 Times/Week | RX-3117 500 mg, 3 Times/Week | RX-3117 1000 mg, 3 Times/Week | RX 3117 1500 mg, 3 Times/Week | RX-3117 2000 mg, 3 Times/Week | RX-3117 500 mg, 5 Times/Week | RX-3117 700 mg, 5 Times/Week | RX-3117 500 mg, 7 Times/Week |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Safety Profile Characterized by the Number of Subjects That Discontinue Study Treatment - Phase 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
Number of subjects that experience any treatment-related adverse event.
| Participants | RX-3117 30 mg, 3 Times/Week | RX-3117 60 mg, 3 Times/Week | RX-3117 100 mg, 3 Times/Week | RX-3117 150 mg, 3 Times/Week | RX-3117 200 mg, 3 Times/Week | RX-3117 500 mg, 3 Times/Week | RX-3117 1000 mg, 3 Times/Week | RX 3117 1500 mg, 3 Times/Week | RX-3117 2000 mg, 3 Times/Week | RX-3117 500 mg, 5 Times/Week | RX-3117 700 mg, 5 Times/Week | RX-3117 500 mg, 7 Times/Week |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Safety Profile Characterized by Number of Subjects Experiencing a Treatment Emergent Adverse Event- Phase 1 | 0 | 1 | 2 | 3 | 3 | 0 | 2 | 3 | 6 | 3 | 9 | 3 |
Progression Free Survival in Phase 2 of the study for pancreatic and bladder cancer subjects.
| weeks | RX-3117 700 mg 5 Times/Week (Phase 2 Portion of Study) |
|---|---|
| Pancreatic cancer patients | 4.7 (3.14 to 8.00) |
| Bladder cancer patients | 7.7 (7.14 to 13.00) |
No measurements were reported for this outcome.
Best Overall Response Rate (includes Complete Response, Partial Response, and Stable Disease)
| percentage | RX-3117 700 mg 5 Times/Week (Phase 2 Portion of Study) |
|---|---|
| pancreatic subjects | 26.8 (14.2 to 42.9) |
| bladder subjects | 45.2 (27.3 to 64.0) |
Analysis of biomarker data not conducted. Biomarker samples were not analyzed due to previous sponsor terminating clinical program.
No measurements were reported for this outcome.
Collected over up to 224 days (8 cycles of treatment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 (Dose Escalation) 30 mg 3x/Week | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Phase 1 (Dose Escalation) 60 mg 3x/Week | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Phase 1 (Dose Escalation) 100 mg 3x/Week | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1 (Dose Escalation) 150 mg 3x/Week | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1 (Dose Escalation) 200 mg 3x/Week | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1 (Dose Escalation) 500 mg 3x/Week | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Phase 1 (Dose Escalation) 1000 mg 3x/Week | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1 (Dose Escalation) 1500 mg 3x/Week | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Phase 1 (Dose Escalation) 2000 mg 3x/Week | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase 1 (Dose Escalation) 500 mg 5x/Week | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1 (Dose Escalation) 700 mg 5x/Week | 1/11 (9.1%) | 5/11 (45.5%) | 11/11 (100%) |
| Phase 1 (Dose Escalation) 500 mg 7x/Week | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 2 700 mg | 8/80 (10%) | 29/80 (36.3%) | 78/80 (97.5%) |
| Event | Phase 1 (Dose Escalation) 30 mg 3x/Week | Phase 1 (Dose Escalation) 60 mg 3x/Week | Phase 1 (Dose Escalation) 100 mg 3x/Week | Phase 1 (Dose Escalation) 150 mg 3x/Week | Phase 1 (Dose Escalation) 200 mg 3x/Week | Phase 1 (Dose Escalation) 500 mg 3x/Week | Phase 1 (Dose Escalation) 1000 mg 3x/Week | Phase 1 (Dose Escalation) 1500 mg 3x/Week | Phase 1 (Dose Escalation) 2000 mg 3x/Week | Phase 1 (Dose Escalation) 500 mg 5x/Week | Phase 1 (Dose Escalation) 700 mg 5x/Week | Phase 1 (Dose Escalation) 500 mg 7x/Week | Phase 2 700 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| hypoglycemiaMetabolism and nutrition disorders | 0/1 | 1/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/6 | 0/3 | 0/11 | 0/3 | 0/80 |
| pneumoniaInfections and infestations | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/4 | 0/6 | 1/3 | 0/11 | 0/3 | 0/80 |
| stomatitisGastrointestinal disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/6 | 0/3 | 0/11 | 1/3 | 0/80 |
| vomitingGastrointestinal disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/6 | 1/3 | 0/11 | 0/3 | 0/80 |
| cerebrovascular accidentNervous system disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/6 | 1/3 | 0/11 | 0/3 | 1/80 |
| pleurisyRespiratory, thoracic and mediastinal disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/6 | 1/3 | 0/11 | 0/3 | 0/80 |
| anemiaBlood and lymphatic system disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 1/6 | 0/3 | 0/11 | 0/3 | 0/80 |
| neutropeniaBlood and lymphatic system disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 1/6 | 0/3 | 0/11 | 0/3 | 0/80 |
| urinary tract obstructionRenal and urinary disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 1/6 | 0/3 | 0/11 | 0/3 | 1/80 |
| haematemesisGastrointestinal disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/6 | 0/3 | 1/11 | 0/3 | 0/80 |
| Event | Phase 1 (Dose Escalation) 30 mg 3x/Week | Phase 1 (Dose Escalation) 60 mg 3x/Week | Phase 1 (Dose Escalation) 100 mg 3x/Week | Phase 1 (Dose Escalation) 150 mg 3x/Week | Phase 1 (Dose Escalation) 200 mg 3x/Week | Phase 1 (Dose Escalation) 500 mg 3x/Week | Phase 1 (Dose Escalation) 1000 mg 3x/Week | Phase 1 (Dose Escalation) 1500 mg 3x/Week | Phase 1 (Dose Escalation) 2000 mg 3x/Week | Phase 1 (Dose Escalation) 500 mg 5x/Week | Phase 1 (Dose Escalation) 700 mg 5x/Week | Phase 1 (Dose Escalation) 500 mg 7x/Week | Phase 2 700 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| nauseaGastrointestinal disorders | 0/1 | 0/1 | 2/3 | 1/3 | 1/3 | 0/3 | 1/3 | 1/4 | 2/6 | 0/3 | 6/11 | 3/3 | 22/80 |
| abdominal painGastrointestinal disorders | 1/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/6 | 0/3 | 3/11 | 0/3 | 23/80 |
| fatigueGeneral disorders | 0/1 | 1/1 | 2/3 | 2/3 | 2/3 | 0/3 | 1/3 | 3/4 | 4/6 | 1/3 | 6/11 | 1/3 | 39/80 |
| decreased appetiteMetabolism and nutrition disorders | 0/1 | 1/1 | 0/3 | 1/3 | 0/3 | 0/3 | 1/3 | 0/4 | 1/6 | 1/3 | 3/11 | 0/3 | 15/80 |
| hypomagnesaemiaMetabolism and nutrition disorders | 1/1 | 0/1 | 0/3 | 1/3 | 0/3 | 0/3 | 1/3 | 0/4 | 0/6 | 0/3 | 0/11 | 0/3 | 4/80 |
| coughRespiratory, thoracic and mediastinal disorders | 0/1 | 1/1 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/4 | 0/6 | 0/3 | 2/11 | 0/3 | 7/80 |
| vomitingGastrointestinal disorders | 0/1 | 0/1 | 2/3 | 1/3 | 0/3 | 0/3 | 1/3 | 0/4 | 1/6 | 1/3 | 4/11 | 2/3 | 14/80 |
| anaemiaBlood and lymphatic system disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 2/3 | 0/4 | 3/6 | 2/3 | 4/11 | 2/3 | 38/80 |
| lymphocyte count decreasedInvestigations | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 2/6 | 2/3 | 0/11 | 0/3 | 0/80 |
| diarrhoeaGastrointestinal disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/6 | 0/3 | 0/11 | 0/3 | 37/80 |
| Age, Continuous(years) | RX-3117 30 mg 3 Times/Week | RX-3117 60 mg 3 Times/Week | RX-3117 100 mg 3 Times/Week | RX-3117 150 mg 3 Times/Week | RX-3117 200 mg 3 Times/Week | RX-3117 500 mg 3 Times/Week | RX-3117 1000 mg 3 Times/Week | RX-3117 1500 mg 3 Times/Week | RX-3117 2000 mg 3 Times/Week | RX-3117 500 mg 5 Times/Week | RX-3117 700 mg 5 Times/Week | RX-3117 500 mg 7 Times/Week | RX-3117 700 mg 5 Times/Week (Phase 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 69.0 ± 0 | 66.0 ± 0 | 65.3 ± 5.86 | 67.0 ± 4.58 | 68.0 ± 6.24 | 53.7 ± 7.57 | 54.3 ± 4.16 | 63.3 ± 16.50 | 61.0 ± 13.30 | 62.0 ± 13.08 | 58.0 ± 10.87 | 67.0 ± 6.56 | 67.6 ± 9.11 | 65.37 ± 9.84 |
| Sex: Female, Male(Participants) | RX-3117 30 mg 3 Times/Week | RX-3117 60 mg 3 Times/Week | RX-3117 100 mg 3 Times/Week | RX-3117 150 mg 3 Times/Week | RX-3117 200 mg 3 Times/Week | RX-3117 500 mg 3 Times/Week | RX-3117 1000 mg 3 Times/Week | RX-3117 1500 mg 3 Times/Week | RX-3117 2000 mg 3 Times/Week | RX-3117 500 mg 5 Times/Week | RX-3117 700 mg 5 Times/Week | RX-3117 500 mg 7 Times/Week | RX-3117 700 mg 5 Times/Week (Phase 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 1 | 4 | 2 | 8 | 3 | 34 | 63 |
| Male | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 3 | 2 | 1 | 3 | 0 | 46 | 61 |
| Ethnicity (NIH/OMB)(Participants) | RX-3117 30 mg 3 Times/Week | RX-3117 60 mg 3 Times/Week | RX-3117 100 mg 3 Times/Week | RX-3117 150 mg 3 Times/Week | RX-3117 200 mg 3 Times/Week | RX-3117 500 mg 3 Times/Week | RX-3117 1000 mg 3 Times/Week | RX-3117 1500 mg 3 Times/Week | RX-3117 2000 mg 3 Times/Week | RX-3117 500 mg 5 Times/Week | RX-3117 700 mg 5 Times/Week | RX-3117 500 mg 7 Times/Week | RX-3117 700 mg 5 Times/Week (Phase 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 3 | 1 | 5 | 1 | 14 | 31 |
| Not Hispanic or Latino | 1 | 0 | 2 | 2 | 2 | 2 | 1 | 4 | 3 | 2 | 6 | 2 | 63 | 90 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Race (NIH/OMB)(Participants) | RX-3117 30 mg 3 Times/Week | RX-3117 60 mg 3 Times/Week | RX-3117 100 mg 3 Times/Week | RX-3117 150 mg 3 Times/Week | RX-3117 200 mg 3 Times/Week | RX-3117 500 mg 3 Times/Week | RX-3117 1000 mg 3 Times/Week | RX-3117 1500 mg 3 Times/Week | RX-3117 2000 mg 3 Times/Week | RX-3117 500 mg 5 Times/Week | RX-3117 700 mg 5 Times/Week | RX-3117 500 mg 7 Times/Week | RX-3117 700 mg 5 Times/Week (Phase 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 8 | 10 |
| White | 1 | 1 | 3 | 3 | 3 | 1 | 1 | 3 | 5 | 3 | 9 | 2 | 64 | 99 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 5 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Dec 2013, a primary completion of Jul 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2023, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Processa Pharmaceuticals